Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-12 5:06 pm Unchanged | 2026-02-18 | 13D | Q32 Bio Inc. QTTB | ORBIMED ADVISORS LLC | 2,252,987 15.400% | 0 (Unchanged) | Filing History |
| 2026-03-04 9:12 pm Sale | 2026-03-02 | 13D | PMV Pharmaceuticals, Inc. PMVP | ORBIMED ADVISORS LLC | 0 0.000% | -4,975,291 (Position Closed) | Filing History |
| 2026-02-17 6:33 pm Unchanged | 2025-12-31 | 13G | VistaGen Therapeutics, Inc. VTGN | ORBIMED ADVISORS LLC | 1,639,700 4.200% | 0 (Unchanged) | Filing History |
| 2026-02-17 6:27 pm Purchase | 2025-12-31 | 13G | InspireMD, Inc. NSPR | ORBIMED ADVISORS LLC | 3,133,405 7.400% | 1,000,000 (+46.87%) | Filing History |
| 2026-02-17 6:23 pm Sale | 2025-12-31 | 13G | CytomX Therapeutics, Inc. CTMX | ORBIMED ADVISORS LLC | 3,525,650 2.100% | -4,935,850 (-58.33%) | Filing History |
| 2026-02-17 6:20 pm Purchase | 2025-12-31 | 13G | Cybin Inc. CYBN | ORBIMED ADVISORS LLC | 2,422,600 4.900% | 2,422,600 (New Position) | Filing History |
| 2026-02-17 6:18 pm Sale | 2025-12-31 | 13G | C4 Therapeutics, Inc. CCCC | ORBIMED ADVISORS LLC | 883,534 1.000% | -2,684,812 (-75.24%) | Filing History |
| 2026-02-17 6:13 pm Purchase | 2025-12-31 | 13G | Avalo Therapeutics, Inc. AVTX | ORBIMED ADVISORS LLC | 1,187,300 6.400% | 220,300 (+22.78%) | Filing History |
| 2026-02-17 6:06 pm Sale | 2025-12-31 | 13G | ADC Therapeutics S.A. ADCT | ORBIMED ADVISORS LLC | 3,230,797 2.600% | -207,016 (-6.02%) | Filing History |
| 2026-02-11 6:42 pm Sale | 2026-02-05 | 13D | MBX Biosciences, Inc. Common Stock MBX | ORBIMED ADVISORS LLC | 3,637,887 7.700% | -365,000 (-9.12%) | Filing History |
| 2026-01-27 8:38 pm Sale | 2026-01-23 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 8,609,091 10.300% | -1,176,332 (-12.02%) | Filing History |
| 2025-11-14 6:18 pm Sale | 2025-09-30 | 13G | RAPT Therapeutics, Inc. RAPT | ORBIMED ADVISORS LLC | 1,086,618 6.600% | -555,290 (-33.82%) | Filing History |
| 2025-11-14 6:12 pm Unchanged | 2025-09-30 | 13G | InspireMD, Inc. NSPR | ORBIMED ADVISORS LLC | 2,133,405 4.100% | 0 (Unchanged) | Filing History |
| 2025-11-14 6:08 pm Sale | 2025-09-30 | 13G | C4 Therapeutics, Inc. CCCC | ORBIMED ADVISORS LLC | 3,568,346 5.000% | -1,087,254 (-23.35%) | Filing History |
| 2025-11-14 6:04 pm Purchase | 2025-09-30 | 13G | VistaGen Therapeutics, Inc. VTGN | ORBIMED ADVISORS LLC | 1,639,700 5.340% | 1,639,700 (New Position) | Filing History |
| 2025-11-05 4:13 pm Sale | 2025-11-03 | 13D | Terns Pharmaceuticals, Inc. TERN | ORBIMED ADVISORS LLC | 4,240,068 4.800% | -3,322,903 (-43.94%) | Filing History |
| 2025-10-27 5:12 pm Sale | 2025-10-23 | 13D | PMV Pharmaceuticals, Inc. PMVP | ORBIMED ADVISORS LLC | 4,975,291 9.400% | -1,587,786 (-24.19%) | Filing History |
| 2025-10-10 7:55 pm Purchase | 2025-10-08 | 13D | Adicet Bio, Inc. ACET | ORBIMED ADVISORS LLC | 923,287 9.600% | 312,500 (+51.16%) | Filing History |
| 2025-09-30 7:06 pm Purchase | 2025-09-26 | 13D | MBX Biosciences, Inc. Common Stock MBX | ORBIMED ADVISORS LLC | 4,002,887 9.000% | 190,672 (+5.00%) | Filing History |
| 2025-09-02 9:53 pm Purchase | 2025-08-25 | 13D | Shattuck Labs, Inc. STTK | ORBIMED ADVISORS LLC | 6,306,127 9.990% | 6,306,127 (New Position) | Filing History |